Online Program Home
My Program

CC = Colorado Convention Center   H = Hyatt Regency Denver at Colorado Convention Center
* = applied session       ! = JSM meeting theme

Activity Details

355 Tue, 7/30/2019, 10:30 AM - 12:20 PM CC-Hall C
Contributed Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations
Biopharmaceutical Section
Chair(s): Wendy Meiring, University of California At Santa Barbara
1: Some Tests for the Assessment of Univariate and Multivariate Bioequivalence
Rabab Elnaiem, University of Maryland, Baltimore County; Thomas Mathew, University of Maryland, Baltimore County
2: A Comparison of Methods to Estimate the Event Rate Based on Longitudinal Data
Bo Fu, Astellas Pharma Inc.; Xuan Liu, Astellas Pharma Inc.; Jun Zhao, Astellas Pharma Inc.
3: A Bayesian Answers "Should This Drug Be Approved?"
Konstantinos Vamvourellis, London School of Economics and Politcal Science
5: The Statistics of Synthetically-Controlled Clinical Trials
Aaron Smith, Unlearn.AI; Charles K. Fisher, Unlearn.AI
7: Nonparametric Bayesian Method for Drug Combination with Discrete Doses
Zahra Razaee, Cedars-Sinai Medical Center; Galen Cook-Wiens, Cedars Sinai Medical Center; Mourad Tighiouart, Cedars-Sinai Medical Center
8: Estimand and Analysis Consideration in a Phase III Study of CAR-T with Delayed Treatment Effect - a Case Study of Lymphoma
Wen Gu, Novartis Pharmaceutical Inc.
9: A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Quasi-Continuous Toxicity Index
Sungjin Kim, Cedars-Sinai Medical Center; Zahra Razaee, Cedars-Sinai Medical Center; Andre Rogatko, Cedars-Sinai Medical Center; Mourad Tighiouart, Cedars-Sinai Medical Center
10: Assessing the Performance of Different Outcomes for Tumor Growth Studies with Animal Models
Luke William Patten, Center for Innovative Design and Analysis, University of Colorado, Anschutz Medical Campus; Alexander Kaizer, University of Colorado Anschutz Medical Campus; Patrick Blatchford, University of Colorado
11: Equivalency Test Based on Combinations of Mean and Variance Components in the One-Way Random Effects Model with Application to Device Comparison Study
Yun Bai, Medtronic; BAOLIN WU, University of Minnesota; Zengri Wang, Medtronic plc; Theodore Lystig, Medtronic
Tao Sheng
13: A Comparison of Migraine Prevention Therapies in the Adult Versus Pediatric Populations Using a Joint Bayesian Network Meta-Analysis Model
Zachary Thomas, Eli Lilly and Company; Phebe Kemmer, Eli Lilly and Company; Tianle Hu, Eli Lilly and Company; Fanni Natanegara, Eli Lilly and Company; Himanshu Upadhyaya, Eli Lilly and Company
14: Dose-Finding Designs Using Time-To-Event Toxicity Data and Multiple Constraints
Meizi Liu, University of Chicago
16: Wearable Devices in Clinical Trials: Making an Impact in the Cardiovascular Space
Vanja Vlajnic; Chrysanthi Dori, Bayer; Mercedeh Ghadessi, Bayer; Stephan Cichos, Bayer; Maike Ahrens, Bayer; Matthias Sachs, Bayer / SAMSI; Paolo Piraino, Bayer
17: Combining Tabular Data with Visual Display to Enhance Interpretation of Clinical Trial Data
Teresa Curto, Cytel; Ashish Aggarwal , Cytel; Angelo Tinazzi , Cytel
18: Tumor-Growth Modeling for Informed Go/No-Go Decisions
Wei Wei, Yale University School of Public Health; Daniel Zelterman, Yale University School of Public Health; Elizabeth Garrett-Mayer, American Society of Clinical Oncology
19: Less Is More – Adaptive Seamless Phase II/III Design
Helen Chen, GSK; Jonathan Haddad , GlaxoSmithKline; Xiaowei Wang, GlaxoSmithKline
20: Estimate of Treatment Difference for Non-Normally Distributed Data in Clinical Trials – Comparison of Hodges-Lehmann Method and Quantile Regression
Youlan Rao, United Therapeutics Corporation; Yonggang Yao, SAS Institute Inc; Lisa Edwards, United Therapeutics Corporation; Chunqin Deng, United Therapeutics Corporation
21: Sequential Multiple Assignment Randomized Trials with Continuous Intermediate Outcome
Holly Elizabeth Hartman, University of Michigan; Kelley Kidwell, University of Michigan; Matthew J. Schipper, University of Michigan
22: Statistical Considerations for Analytical Method Transfer Equivalence Margin
Oluyemi Oyeniran, JNJ; Jyh-Ming Shoung, Janssen R&D
23: Quantifying Impact of Enrichment in Randomized Clinical Trials
Navneet Hakhu, University of California, Irvine; Daniel L. Gillen, University of California, Irvine
24: Predicting Unmeasured Outcomes in the Real-World Data: Bayesian and Frequentist Approaches - a Simulation Study
Wenyu Ye, Eli Lilly and Company; Douglas Faries, Eli Lilly & Company; Xiang Zhang, Eli Lilly and Company; janet ford, Eli Lilly and compnay; zbigniew kadziola, Eli Lilly and company; Xiaojuan Mi, TechData Service Company, LLC; Ilya Lipkovich, Eli Lilly and Company
26: High-Throughput Screening of Features Which Moderate Treatment Effect on Clinical Outcome
Kushal Shah, University of North Carolina (UNC); Michael Kosorok, University of North Carolina at Chapel Hill
27: Non-Collapsibility of Hazard Ratio
Busola Sanusi, The University of North Carolina; Godwin Yung, Takeda Pharmaceuticals; Yi Liu, Takeda Pharmaceuticals International Co.
28: Using BLRM to Find MTDs for Loading Dose and Maintenance Dose in Oncology Trials
Kejian Liu, Sanofi; Yinge Sun, University of Virginia
29: Machine Learning for Protein Design
Yuting Xu, Merck Sharp & Dohme Corp.; Andy Liaw, Merck Sharp & Dohme Corp.
30: Mediation by Progression of Treatment-Related Differences in Patient Reported Outcomes (PROs) in Oncology
Michael Blackowicz, Clinical Outcomes Solutions; Alicyn Campbell, Patient Relevant Evidence; Lysbeth Floden, Clinical Outcomes Solutions; Stacie Hudgens, Clinical Outcomes Solutions; Ethan Basch, University of North Carolina Lineberger Comprehensive Cancer Center
31: The Role of HLA-Class-II (HLAcII) Molecules in Determining the Immunogenicity Potential of Therapeutic Factor VIII Proteins (TFVIIIs) in Hemophilia a (HA): Assessing the Gate Keepe
Henry Mead, Walden University
32: Continuous Glucose Monitoring Technology and a Workflow for Its Data Analysis
Dandan Wang, Faculty of Health Sciences, Univerity of Macau; Xiaohua Douglas Zhang, University of Macau; Zhaozhi Zek Zhang, Washington University
34: Integrative Variable Selection Method for Subgroup Analyzes in Longitudinal Data
Xiaochen Li, Indiana University; Sujuan Gao, Indiana University
35: Bias-Correction in Estimating Treatment Effect in Fallback Analysis: An Approach Based on Randomized Test with Smooth Rejection Functions
Kiichiro Toyoizumi, Shionogi Inc.; Shigeyuki Matsui, Nagoya University Graduate School of Medicine
36: Identifying Two-Stage Optimal Dynamic Treatment Regimes: Compare Performances of Different Methods Under Model Misspecification
Sooyeong Lim, Miami University; Chen Chen, Cincinnati Children's Hospital; Rhonda Szczesniak, Cincinnati Children's Hospital; Gary Lewis McPhail, Cincinnati Children's Hospital; Bin Huang, Cincinnati Children's Hospital
37: Stepwise Progressive Parametric Multiple Testing Procedure with Correlated Normal Test Statistics
Xuan Deng, Merck; Mark Chang, Veristat
38: Quantitative Reproducibility Analysis for Identifying Reproducible Targets from High-Throughput Experiments
Wenfei Zhang, Sanofi (United States)
39: An Event/Trial Binomial Model for Meaningful Change Inference in Randomized Clinical Trials
Daniel Serrano, Pharmerit International
40: Model Averaging of Bayesian Additive Regression Trees via Approximate Gaussian Processes
Kijoeng Nam, Merck; Nicholas Henderson, Johns Hopkins University; Dai Feng, AbbVie
41: Cancer Immunotherapy Trial Design with Delayed Treatment Effect
Jing Wei, no
42: A Personalized Medicine Approach for Comparative Evidence in Non-Randomized Studies
Carl De Moor, Biogen; Lu Tian, Stanford University School of Medicine; Fabio Pellegrini, Biogen International GmbH
43: Sample Size Calculation for the Andersen-Gill Model Comparing Rates of Recurrent Events
Ronan Fitzpatrick, Statsols; Yongqiang Tang, Tesaro
44: Mining Longitudinal Real-World Data to Identify Risk Factors for Cardiovascular Events Related to Anti-Dementia Medications
Meiqi He, University of Pittsburgh School of Pharmacy; Yuting Zhang, University of Melbourne Institute of Applied Economic and Social Research; Inmaculada Hernandez, University of Pittsburgh School of Pharmacy
45: Bootstrap Calibration for Parametric Tolerance Intervals to Improve Coverage Probabilities
Yixuan Zou, University of Kentucky; Derek Young, University of Kentucky
46: Evaluating the Effects of Design Parameters on the Performances of Phase I Trial Designs
Yaqian Zhu, University of Pennsylvania; Wei-Ting Hwang, University of Pennsylvania; Yimei Li, University of Pennsylvania